Please complete the CAPTCHA to continue
@agios.com
✓
3 phones found area 602 and 617
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Deborah Franke Speranzo is listed as Gene Therapy | Rare Disease | Biotech | Commercial Director | Pre-Approval & Post-Launch Strategy | at Sobi - North America, based in United States, United States, United States. AeroLeads shows a work email signal at agios.com, phone signal with area code 602, 617, and a matched LinkedIn profile for Deborah Franke Speranzo.
Deborah Franke Speranzo previously worked as Commercial Business Director - Health Systems at Sobi - North America and Director, Gene Therapy at Biomarin Pharmaceutical Inc.. Deborah Franke Speranzo studied at The University Of Texas At Austin.
This section adds company-level context without repeating Deborah Franke Speranzo's masked contact details.
AeroLeads found 1 current-domain work email signal for Deborah Franke Speranzo. Compare company email patterns before reaching out.
Experienced Executive Sales Director commercial strategic leader with demonstrated history of successful product launches in rare disease, AAV gene therapy, neuromuscular, SMA, neurology, oncology, dermatology and hematology. Experience leading strategy and execution of elite field collaboration teams including sales, reimbursement, channel and advocacy teams calling on both pediatric and adult hospitals as well as community accounts. Skilled in complex multi-million dollar gene therapy models requiring partnership across all facets of healthcare system including hospital P&T, EMR, SOPs, procurement, administration, infusion site readiness and integration. Highly adept at building launch teams that excell at pre and post launch execution, building/acheiving KPI metrics, strategic account development, reimbursement, buy and bill, market access and community advocacy. Graduated from The University of Texas at Austin.
Listed skills include Rheumatology, Oncology, Dermatology, Pharmaceutical Industry, and 26 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Within the therapeutic area haematology, immunology and specialty care, Sobi is dedicated to the treatment of rare, ultra-rare and severe diseases. This dedication combined with a rare expertise has resulted in a long history of developing transformative treatments for patients with high unmet medical needs. Our ability to identify unmet medical needs.
San Rafael, CA, US
At BioMarin, through our unparalleled expertise in genetics and molecular biology, we will continue to develop targeted therapies that address the root cause of the conditions we seek to treat. Applying our knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most. Transforming lives through genetic.
Cambridge, MA, US
Where science meets heart. Passionately committed to transforming the lives of people with genetically defined rare diseases including Pyruvate Kinase Deficiency (PKD), Thalassemias and Sickle-Cell Disease.
Basel, Baselstadt, CH
AveXis is now Novartis Gene Therapies. Novartis Gene Therapies is dedicated to developing and commercializing gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. (SMA, Spinal Muscle Atrophy, rare neurological disease, gene therapy, Zolgensma)
At AveXis, we work relentlessly to bring gene therapy to patients and families affected by rare and life-threatening neurological genetic diseases, like spinal muscular atrophy (SMA), Rett syndrome (RTT), and a genetic form of amyotrophic lateral sclerosis (ALS). Our dedication to advancing gene-based medicine can make a difference in the fight against.
Waltham, MA, US
Hemophilia, rare disease2014 President's Circle Winner2016 President's Circle WinnerBioverativ is dedicated to transforming the lives of people with hemophilia, cold agglutinin disease and other rare blood disorders. As an independent biopharmaceutical company spun out of Biogen’s hemophilia business, it brings a strong legacy of innovation, world-class.
Cambridge, MA, US
Hemophilia, rare disease2014 President's Circle Winner2016 President's Circle WinnerBiogen is a pioneer in neuroscience. Since its founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological and hematologic diseases.
Phoenix, AZ, US
Avella is a national specialty pharmacy dedicated to empowering patients, providers and other organizations across the entire healthcare continuum. Invested in improving the health—and the lives—of the people they serve, Avella accomplishes this goal by acting as expert clinicians, passionate advocates, committed healthcare partners and strategic innovators.
Thousand Oaks, CA, US
Amgen was incorporated on April 8, 1980, in Thousand Oaks, California, during the dawn of biotechnology. The company was created around a simple idea—that emerging research in biology could lead to meaningful advances if the right scientists could be assembled and given the appropriate resources. Since then, Amgen has grown to be one of the world's leading.
Thousand Oaks, CA, US
Strategic Training Manager - Inflammation Business Unit
Thousand Oaks, CA, US
Immunex was acquired by Amgen in 2002
Lawrence Township, NJ, US
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.Deborah's areas of focus at BMS was Cardiology, Endocrinology, Neurology, Internal Medicine & Primary Care Sales.
Quick answers generated from the profile data available on this page.
Deborah Franke Speranzo works for Sobi - North America.
Deborah Franke Speranzo is listed as Gene Therapy | Rare Disease | Biotech | Commercial Director | Pre-Approval & Post-Launch Strategy | at Sobi - North America.
AeroLeads has found 1 work email signal at @agios.com for Deborah Franke Speranzo at Sobi - North America.
AeroLeads has found 3 phone signal(s) with area code 602, 617 for Deborah Franke Speranzo at Sobi - North America.
Deborah Franke Speranzo is based in United States, United States, United States while working with Sobi - North America.
Deborah Franke Speranzo has worked for Sobi - North America, Biomarin Pharmaceutical Inc., Agios Pharmaceuticals, Novartis Gene Therapies, and Avexis, Inc..
You can use AeroLeads to view verified contact signals for Deborah Franke Speranzo at Sobi - North America, including work email, phone, and LinkedIn data when available.
Deborah Franke Speranzo studied at The University Of Texas At Austin.
Deborah Franke Speranzo is listed with skills including Rheumatology, Oncology, Dermatology, Pharmaceutical Industry, Neurology, Cardiology, Pharmaceutical Sales, and Hematology.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts